MiNK Therapeutics, Inc.
Income Statement
| Line Item | Aug 2025 | Jun 2025 | May 2025 | Mar 2025 | Mar 2025 | Dec 2024 | Nov 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.8M | — | $1.3M | — | — | — | $540.6K |
| SG&A Expense | — | $1.8M | — | $1.3M | — | — | — | $1.2M |
| Operating Income | — | $-4.1M | — | $-2.7M | — | — | — | $-1.9M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | $-27.0K | — | $-29.0K | — | — | — | $-28.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-4.2M | — | $-2.8M | — | — | — | $-1.8M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.06 | — | $-0.70 | — | — | — | $-0.46 |
| EPS (Diluted) | — | $-1.06 | — | $-0.70 | — | — | — | $-0.46 |
| Shares Outstanding (Basic) | 4.5M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 39.5M | 4.0M |
| Shares Outstanding (Diluted) | 4.5M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 39.5M | 4.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |